Effect of supplementation in treatment of patients with polycystic ovary syndrome

Clinical trial of the effect of coenzyme Q10 supplementation compared with the placebo on gene expression related to inflammation and lipid in patients with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201612315623N97

Enrollment

Registered

2017-01-02

Start date

2016-11-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovary syndrome

Interventions

Intervention 1: Intervention group: 100 mg coenzyme Q10 (Nature, New York, USA), once a day, for 12 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran), once a day, for

Treatment - Drugs

Intervention group: 100 mg coenzyme Q10 (Nature, New York, USA), once a day, for 12 weeks orally.

Control group: Placebo (Barij Essence, Kashan, Iran), once a day, for 12 weeks orally.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with polycystic ovary syndrome; aged 18 to 40 years. Exclusion criteria: Unwillingness to cooperate.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
TNF-a. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR-RT.;IL-1. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR-RT.	—

Secondary

Measure	Time frame
Ox-LDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR-RT.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026